Support PBS listing for pembrolizumab
6 May 2019
Following the November 2018 PBAC meeting, pembrolizumab has been resubmitted to the Pharmaceutical Benefits Advisory Committee (PBAC) meeting in July 2019 to seek reimbursement on the PBS for the adjuvant treatment of patients with resected stage III melanoma.
Listing on the Australian Pharmaceutical benefits scheme would provide subsidised access to this treatment for resected stage III melanoma.
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions in support of the PBS listing.
Submissions will be accepted until Wed 12 June 2019, and they can be made as follows:
- Email your input directly to the PBAC at CommentsPBAC@health.gov.au
- Mail your submission to the PBAC Secretariat: MDP 952, Department of Health and Ageing, GPO Box 9848, Canberra ACT 2601
- There is also an online portal for submission
Please note that if you are submitting via the online portal, there are two submissions for pembrolizumab. Please select the option that states Indication: Melanoma – the first pembrolizumab option.
MIA's dermatologist shares her knowledge with GPs on debunking myths and controversies on sunscreen.
Shannan Ponton thought he was invincible – he wasn’t. But his melanoma battle ended up saving more than his own life.
Researchers have demonstrated that immunotherapy is highly effective in treating a rare form of melanoma – a result that is surprising due to the nature of the tumour.
Innovation is helping to prevent melanoma developing in the first place.
Research from MIA is changing the way melanoma is managed worldwide and improving patient survival. Here are a few of our key highlights from this year.
A prestigious Fellowship has been awarded to fund research that will change the way melanoma treatment is assessed in the future.
New research from MIA has been published that forms the basis of the updated international guidelines for staging melanoma.
Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
2018 will be bigger than ever, and a little bit different.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.